Omalizumab
Omalizumab
Omalizumab (pronounced oh-ma-li-ZOO-mab) is a monoclonal antibody medication used in the treatment of moderate to severe asthma and chronic idiopathic urticaria.
Etymology
The name "Omalizumab" is derived from the International Nonproprietary Names (INN), in which 'Oma' is taken from the word 'human', 'li' stands for 'immunoglobulin', and 'zumab' is a suffix used for humanized antibodies.
Usage
Omalizumab is primarily used to treat asthma and chronic idiopathic urticaria. It is specifically used for patients with severe allergic asthma that is not controlled by inhaled corticosteroids. It works by binding to the IgE antibodies in the body, reducing the number of IgE antibodies available to trigger an allergic reaction.
Side Effects
Common side effects of Omalizumab include injection site reactions, viral infections, upper respiratory tract infection, sinusitis, headache, and sore throat. Severe side effects may include anaphylaxis, heart attack, and stroke.
Related Terms
- Monoclonal Antibodies
- Asthma
- Chronic Idiopathic Urticaria
- Immunoglobulin E (IgE)
- Anaphylaxis
- Corticosteroids
External links
- Medical encyclopedia article on Omalizumab
- Wikipedia's article - Omalizumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski